The FDA on Friday recommended new warnings for pediatric use of Suprane, Baxter International's inhaled anesthetic, and Colazal, Salix Pharmaceuticals Ltd.'s anti-inflammatory drug. The agency said Suprane should address cardiac arrest risk following three reported cases among children, while Colazal should have warnings on heart and lung risks that other drugs in the same class carry.

Related Summaries